Head-to-head evidence
DBPR108 vs Henagliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
DBPR108
Developed by CSPC Pharmaceutical Group
NCT04161430 · Phase 3 · completed
In this randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial, 766 patients with type 2 diabetes were randomized to DBPR108, sitagliptin, or placebo. DBPR108 reduced HbA1c significantly more than placebo at 24 weeks, with a treatment difference whose confidence interval excluded no effect.
Henagliflozin
Developed by Jiangsu Hengrui Pharmaceuticals
NCT03159052 · Phase 3 · status unknown
This was a randomized, quadruple-blind, placebo-controlled trial (n=450). The primary endpoint, HbA1c change at 24 weeks, was clearly met: both the 5 mg and 10 mg doses reduced HbA1c significantly more than placebo (p<.001 for each).
Next expected readout: December 2026 · NCT06448130 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: DBPR108's landscape · Henagliflozin's landscape